Earnings ·
Zymeworks Inc. reported second quarter 2026 financial results with total revenue of $4.6 million and a net loss of…
ZYMEZymeworks Inc.
Zymeworks Inc. reported second quarter 2026 financial results with total revenue of $4.6 million and a net loss of $45.0 million, compared to $48.7 million in revenue and a $2.3 million net income in the prior year period. The company holds $322.5 million in cash resources as of June 30, 2026. Key developments include an August 25, 2026 U.S. PDUFA target action date for zanidatamab, which carries a potential $250 million approval milestone, and the expected closing of the Theravance Biopharma acquisition in the second half of 2026 to diversify revenue streams. Additionally, Zymeworks repurchased $49.4 million of common shares under its current program. The company operates as a biotechnology firm managing licensed healthcare assets and developing biotherapeutics.